Showing results (5451-5460 of 5,703) with videos related to

Sort By:
Pageof 571
The Oncologist|June 24, 2018
Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, et al.
The Oncologist|February 13, 2015
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human useZahra Hanaizi, Beatriz Flores, Robert Hemmings, et al.
The Oncologist|February 13, 2015
Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancerJeong-Yeol Park, Joo-Hyun Nam
The Oncologist|February 7, 2015
Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkersJulian C Y Ip, Tony C Y Pang, Anthony R Glover, et al.
The Oncologist|February 12, 2015
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centersCarmelo Carlo-Stella, Francesca Ricci, Serena Dalto, et al.
The Oncologist|April 27, 2023
A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical TrialArash Asher, Celina H Shirazipour, Jessica M Capaldi, et al.
The Oncologist|April 27, 2023
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated CancersVan K Morris, Amir Jazaeri, Shannon N Westin, et al.
The Oncologist|February 28, 2015
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancerMarina Pekar-Zlotin, Fred R Hirsch, Lior Soussan-Gutman, et al.
The Oncologist|July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCarl M Gay, Yanhong Zhou, J Jack Lee, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
Pageof 571